Identifying biomarkers in patients with skin lymphomas.
Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.
This study is trying to find specific markers in the blood and skin of people with skin lymphomas to see if they can help improve treatment options for patients with Mycosis Fungoides and Sézary Syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Lund University Hospital Academic / other |
| Locations | 1 site (Lund) |
| Trial ID | NCT04904146 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify prognostic and treatment-predictive biomarkers in patients diagnosed with Mycosis Fungoides and Sézary Syndrome. It involves blood tests and analyses of the lymphoma microenvironment, skin barrier, and skin microbiology profile. The study includes patients aged 18 to 100 years with confirmed stages I-IV of these conditions. By understanding these biomarkers, the study seeks to enhance treatment strategies for affected individuals.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-100 with histologically confirmed Mycosis Fungoides or Sézary Syndrome.
Not a fit: Patients without a confirmed diagnosis of Mycosis Fungoides or Sézary Syndrome may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with Mycosis Fungoides and Sézary Syndrome.
How similar studies have performed: While similar studies have explored biomarkers in skin lymphomas, this specific approach focusing on prognostic and treatment-predictive biomarkers is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-100 years * Histologically confirmed (according to the World Health Organization (WHO)/EORTC classification) MF/SS stages I-IV * WHO performance status 0 -3 * Absence of psychiatric illness or condition which could interfere with the subjects' ability to understand the requirements of the study. * Written informed consent according to International Conference on Harmonization (ICH)/(Good Clinical Practice (GCP), and Swedish regulations * No minimum or maximum required routine laboratory data Exclusion Criteria: Not applicable. No exclusion criteria are specified.
Where this trial is running
Lund
- Lund University Hospital — Lund, Sweden (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.